Atara Biotherapeutics Inc
Change company Symbol lookup
Select an option...
ATRA Atara Biotherapeutics Inc
ZTS Zoetis Inc
HMPT Home Point Capital Inc
KWR Quaker Chemical Corp
TWO Two Harbors Investment Corp
BV Brightview Holdings Inc
PBPB Potbelly Corp
RLJ RLJ Lodging Trust
LHCG LHC Group Inc
KW Kennedy-Wilson Holdings Inc
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. The Company's product candidate, ATA129, is a third-party derived Epstein-Barr virus CTL for the treatment of Epstein-Barr virus (EBV). ATA188 is in development for the treatment of multiple sclerosis. ATA520, which is a third-party donor derived WT1-CTL, targets cancers expressing the antigen Wilms Tumor 1 (WT1). ATA520 is in Phase I clinical trials. The Company's T-cell product candidate, ATA230, which is a third-party derived cytomegalovirus-CTL (CMV-CTL), is in Phase II clinical trials for refractory CMV.

Closing Price
$12.89
Day's Change
-0.61 (-4.52%)
Bid
--
Ask
--
B/A Size
--
Day's High
13.77
Day's Low
12.67
Volume
(Heavy Day)
Volume:
1,965,664

10-day average volume:
917,774
1,965,664

Company Profile

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. The Company's product candidate, ATA129, is a third-party derived Epstein-Barr virus CTL for the treatment of Epstein-Barr virus (EBV). ATA188 is in development for the treatment of multiple sclerosis. ATA520, which is a third-party donor derived WT1-CTL, targets cancers expressing the antigen Wilms Tumor 1 (WT1). ATA520 is in Phase I clinical trials. The Company's T-cell product candidate, ATA230, which is a third-party derived cytomegalovirus-CTL (CMV-CTL), is in Phase II clinical trials for refractory CMV.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
319.55x
Price/Book (MRQ)
2.84x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

April 2021
Current Month
12.5M
Previous Month
13.1M
Percent of Float
15.02%
Days to Cover
19.8938 Days

Share Information

ATRA is in a share class of common stock
Float
81.5M
Shares Outstanding
84.1M
Institutions Holding Shares
211
95.75%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Ronald C. RenaudChmn.
  • Pascal TouchonPres.
  • Utpal KoppikarCFO
  • Joseph NewellCOO
  • K. Amar MuruganSr.VP

Address

  • 611 Gateway Blvd Ste 900
  • South San Francisco, CA 94080-7015
  • Phone: (650) 278-8930
  • Fax: (302) 636-5454
  • http://www.atarabio.com/

Insider Trading

During the most recent quarter, 63K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.